Compare CCS & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCS | DNTH |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2014 | 2018 |
| Metric | CCS | DNTH |
|---|---|---|
| Price | $57.79 | $78.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $70.50 | ★ $123.09 |
| AVG Volume (30 Days) | 206.8K | ★ 1.1M |
| Earning Date | 04-22-2026 | 03-09-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 4.86 | N/A |
| Revenue | ★ $4,117,816,000.00 | $2,036,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.84 | $30.33 |
| P/E Ratio | $11.40 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $50.42 | $13.37 |
| 52 Week High | $76.00 | $88.45 |
| Indicator | CCS | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 34.89 | 67.84 |
| Support Level | $56.72 | $33.94 |
| Resistance Level | $66.17 | $88.45 |
| Average True Range (ATR) | 1.77 | 4.88 |
| MACD | -0.26 | -0.13 |
| Stochastic Oscillator | 32.73 | 68.24 |
Century Communities Inc is engaged in the development, design, construction, marketing and sale of single-family attached and detached homes. The company builds and sells homes under its Century Communities and Century Complete brands. Its reportable segments for homebuilding operations are: i) West (California and Washington) ii) Mountain (Arizona, Colorado, Nevada and Utah), iii) Texas, iv) Southeast (Florida, Georgia, North Carolina, South Carolina and Tennessee), v) Century Complete (Alabama, Arizona, Florida, Georgia, Indiana, Kentucky, Michigan, North Carolina, and South Carolina). The company's other reportable segments include: Financial Services and Century Living. The company derives the majority of its revenue from the sale of new homes in the Mountain segment.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.